A pilot randomized, double-blind, placebo-controlled trial published in npj Parkinson’s Disease reported positive findings for a sternum-worn vibrotactile device used as a non-pharmacological adjunct in Parkinson’s disease. The study evaluates a device-based intervention designed to influence symptoms through sensory stimulation. The results add to the growing category of wearable or stimulation-based adjunct approaches aimed at improving patient outcomes without relying solely on dopaminergic or other drug mechanisms. Because the trial is pilot-sized, the key near-term role is informing feasibility and signal strength for future studies. The broader significance for biotech and medtech partnerships is that movement disorders research continues to expand beyond drugs, creating pathways for combination strategies and device-led clinical development.